These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30475198)

  • 21. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical Analysis of Markov Models Used for the Economic Evaluation of Colorectal Cancer Screening: A Systematic Review.
    Silva-Illanes N; Espinoza M
    Value Health; 2018 Jul; 21(7):858-873. PubMed ID: 30005759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision analytic models for Alzheimer's disease: state of the art and future directions.
    Cohen JT; Neumann PJ
    Alzheimers Dement; 2008 May; 4(3):212-22. PubMed ID: 18631970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic Review of Health Economic Impact Evaluations of Risk Prediction Models: Stop Developing, Start Evaluating.
    van Giessen A; Peters J; Wilcher B; Hyde C; Moons C; de Wit A; Koffijberg E
    Value Health; 2017 Apr; 20(4):718-726. PubMed ID: 28408017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.
    Katona C; Livingston G; Cooper C; Ames D; Brodaty H; Chiu E
    Int Psychogeriatr; 2007 Jun; 19(3):345-54. PubMed ID: 17386120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of model-based economic evaluations of diagnostic and therapeutic strategies for lower extremity artery disease.
    Vaidya A; Joore MA; ten Cate-Hoek AJ; Kleinegris MC; ten Cate H; Severens JL
    Thromb Haemost; 2014 Jan; 111(1):19-28. PubMed ID: 24108319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling in economic evaluation of mental health prevention: current status and quality of studies.
    Ha NT; Huong NT; Anh VN; Anh NQ
    BMC Health Serv Res; 2022 Jul; 22(1):906. PubMed ID: 35831821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of interventions that assist caregivers to support people with dementia living in the community: a systematic review.
    Parker D; Mills S; Abbey J
    Int J Evid Based Healthc; 2008 Jun; 6(2):137-72. PubMed ID: 21631819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
    Al Kadour A; Marridi WA; Al-Badriyeh D
    Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second International Pharmacoeconomic Conference on Alzheimer' s Disease.
    Jönsson L; Jönsson B; Wimo A; Whitehouse P; Winblad B
    Alzheimer Dis Assoc Disord; 2000; 14(3):137-40. PubMed ID: 10994654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
    Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
    Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia.
    Pusey H; Richards D
    Aging Ment Health; 2001 May; 5(2):107-19. PubMed ID: 11511058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost of dementia in Europe: a review of the evidence, and methodological considerations.
    Jönsson L; Wimo A
    Pharmacoeconomics; 2009; 27(5):391-403. PubMed ID: 19586077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of psychosocial interventions in reducing grief experienced by family carers of people with dementia: a systematic review.
    Wilson S; Toye C; Aoun S; Slatyer S; Moyle W; Beattie E
    JBI Database System Rev Implement Rep; 2017 Mar; 15(3):809-839. PubMed ID: 28267034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic and critical review of model-based economic evaluations of pharmacotherapeutics in patients with bipolar disorder.
    Mohiuddin S
    Appl Health Econ Health Policy; 2014 Aug; 12(4):359-72. PubMed ID: 24838515
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.